Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz haqimizda

Biz bilan bog'lanish

[email protected]

Bizni kuzating

Instagram
Telegram
LinkedIn

Barcha huquqlar himoyalangan.

Foydalanish shartlari

Bosh sahifa
Bozorlar
Skriner
Yangiliklar
Biz haqimizda

Home

SNTI

S

Senti Biosciences, Inc. (SNTI)

NCM – Real vaqt narxi. Valyuta: USD

0.79

-0.09 (-10.36%)

Yopilishda: Mar 27, 2026, 4:00 PM EDT

0.81

+0.02 (2.46%)

Bozordan keyin: Mar 27, 2026, 7:18 PM EDT

Umumiy
Yangiliklar
Grafik
Hisobotlar
Dividendlar
Kutilma
Egalik
Profil

Senti Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Corporate Update

Senti Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Corporate Update

SOUTH SAN FRANCISCO, Calif., March 27, 2026 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today reported financial results for the fourth quarter of 2025 and full year 2025 and provided a summary of recent pipeline and corporate highlights.

Senti Biosciences to Present Clinical and Translational Data on SENTI-202 at the 11th Annual Innate Killer Conference

Senti Biosciences to Present Clinical and Translational Data on SENTI-202 at the 11th Annual Innate Killer Conference

SOUTH SAN FRANCISCO, Calif., March 23, 2026 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced upcoming presentations featuring clinical and translational data from its SENTI-202 program at the 11th Annual Innate Killer Conference, taking place March 24–25, 2026 in San Diego, California.

Senti Biosciences to Present at Leerink Partners 2026 Global Healthcare Conference

Senti Biosciences to Present at Leerink Partners 2026 Global Healthcare Conference

SOUTH SAN FRANCISCO, Calif., March 03, 2026 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced that Timothy Lu, M.D.

Senti Biosciences to Present at TD Cowen 46th Annual Health Care Conference

Senti Biosciences to Present at TD Cowen 46th Annual Health Care Conference

SOUTH SAN FRANCISCO, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced that Timothy Lu, M.D., Ph.D., Co-Founder and Chief Executive Officer of Senti, will highlight the Company's Gene Circuit technology platform, pipeline progress and strategic priorities, with an emphasis on opportunities for partnership across investment, research and development, manufacturing and clinical collaboration at the TD Cowen 46th Annual Health Care Conference on Monday, March 2, 2026, from 3:10 – 3:40 PM ET.

Senti Bio Participates in Cell & Gene Live Event Highlighting Cutting-Edge Technologies Advancing Cell Therapy Development

Senti Bio Participates in Cell & Gene Live Event Highlighting Cutting-Edge Technologies Advancing Cell Therapy Development

SOUTH SAN FRANCISCO, Calif., Feb. 20, 2026 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced that it participated in a Cell & Gene Live virtual event focused on emerging and enabling technologies designed to advance the development of innovative cell therapies.

$Senti Biosciences Completes Enrollment in Phase 1 Clinical Trial of SENTI-202 for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia (R/R AML)$

Senti Biosciences Completes Enrollment in Phase 1 Clinical Trial of SENTI-202 for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia (R/R AML)

Robust SENTI-202 clinical data presented at ASH 2025 demonstrated deep, MRD-negative, durable complete remissions and a favorable safety profile Company planning for rapid advancement of SENTI-202 into R/R AML pivotal study and evaluating indication expansion to include newly diagnosed AML and pediatric AML; Preparing for FDA discussions in the first half of 2026 SENTI-202 has received Regenerative Medicine Advanced Therapy (RMAT) designation, which may enable an expedited development and review process SOUTH SAN FRANCISCO, Calif., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced the completion of enrollment in its Phase 1 clinical trial evaluating SENTI-202, a first-in-class CD33/FLT3-targeting Logic Gated CAR NK cell therapy, in patients with relapsed or refractory acute myeloid leukemia (R/R AML).

Senti Biosciences Selected for On-Stage Presentation at Healthcare Conference Taipei 2026

Senti Biosciences Selected for On-Stage Presentation at Healthcare Conference Taipei 2026

SOUTH SAN FRANCISCO, Calif., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced that Timothy Lu, M.D., Ph.D., Co-Founder and Chief Executive Officer of Senti, has been selected to deliver an on-stage company presentation at the Healthcare Conference Taipei 2026, co-hosted by J.P. Morgan, UC Berkeley, and the Regent Taipei happening February 10–11, 2026, at the Regent Taipei Hotel.

Videolar

No Data

There is no data to display